Zelnorm most-recalled DTC TV ad, Plavix most motivating

Share this article:

Novartis' DTC television ad for Zelnorm was the most recalled by consumers, while Sanofi-Aventis' 60-second spot for Plavix was the most motivating, according to the latest data from IAG Research, a TV effectiveness ratings company.
According to the rankings data, in the five months ending Aug. 31, 2005, 31 new prescription drug ads across 21 brands, both new and existing, aired on prime-time TV across all broadcast and major cable television networks.
Of the new ads, adults 18 and older most often recalled the latest TV ad for Zelnorm as a treatment for irritable bowel syndrome. A black-and- white film-noir spoof ad for Glaxo-SmithKline's Flonase followed at No. 2.
Sepracor's Lunesta, which launched in April 2005, also scored high in the recall category, ranking fourth out of the top five recalled ads.
In addition to tracking 24-hour recall for brands, the IAG's findings included rankings for ads that were the most successful at motivating viewers who recall them to speak with their doctors about the promoted brand.
Sanofi-Aventis' latest 60-second ad for its cardiovascular drug Plavix encouraged the highest level of "stated intent to take action" among adults 18 and older, relative to the average for all new prescription drug ads launched during the study period. AstraZeneca followed at No. 2  with a 45-second spot for Nexium for the treatment of acid indigestion/reflux.

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.